30/04/2016 02:26:49 Cookie Policy +44 (0) 207 0700 961 Free Membership Login
Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -31.50p -0.80% 3,928.00p 3,941.00p 3,943.00p 4,081.50p 3,928.00p 3,962.50p 3,268,260 16:35:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 16,768.9 2,082.9 151.3 25.7 49,645.35

Astrazeneca (AZN) Latest News (24)

More Astrazeneca News
Astrazeneca Takeover Rumours

Astrazeneca (AZN) Share Charts

1 Year Astrazeneca Chart

1 Year Astrazeneca Chart

1 Month Astrazeneca Chart

1 Month Astrazeneca Chart

Intraday Astrazeneca Chart

Intraday Astrazeneca Chart

Astrazeneca (AZN) Discussions and Chat

Astrazeneca (AZN) Top Chat Posts

DateSubject
29/4/2016
09:20
Astrazeneca Daily Update: Astrazeneca is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AZN. The last closing price for Astrazeneca was 3,959.50p.
Astrazeneca has a 4 week average price of 4,079.38p and a 12 week average price of 4,051.22p.
The 1 year high share price is 4,634p while the 1 year low share price is currently 3,746p.
There are currently 1,263,883,777 shares in issue and the average daily traded volume is 2,422,293 shares. The market capitalisation of Astrazeneca is £49,645,354,760.56.
29/4/2016
13:14
montyhedge: Good conference call on the future, everything on track.Share price could have a run big time now. With Astra a sitting duck for Pfizer.
26/4/2016
17:14
kevdav0: Is it because of the boards forthcoming results that is sending share price down . Sorry I'm new to this
15/4/2016
08:55
careful: GS and others are often a contrarian indicator. It has worked well for me in the past, with SBRY (target price 150P), Severn trent (target price 900p). With GS you just have to work out what their angle is.
31/3/2016
23:29
philanderer: AstraZeneca is walking a fine line as setbacks put doubt on 2017 target IC VIEW: Chief executive Pascal Soriot forecast a return to sales growth by 2017, but as that deadline creeps closer setbacks like these have made us more sceptical of the group's ability to achieve this target. Investors too are starting to bow out, with the share price falling 15 per cent so far this year. But for now we're keeping our faith in the long-term strategy, but with so much hanging in the balance we’ll be keeping our eyes peeled. Hold. Last IC view: Hold, 4,217p, 5 Feb 2016 article: HTTP://www.investorschronicle.co.uk/2016/03/31/comment/chronic-investor-blog/astrazeneca-is-walking-a-fine-line-as-setbacks-put-doubt-on-target-EDl2RGz7PDB3fBZruATUfM/article.html
16/2/2016
06:15
indianspan: http://www.4-traders.com/ASTRAZENECA-PLC-4000930/news/AstraZeneca-38-1-Potential-Upside-Indicated-by-Deutsche-Bank-21856171/ AstraZeneca plc with EPIC/TICKER had its stock rating noted as Retains with the recommendation being set at BUY this morning by analysts at Deutsche Bank. AstraZeneca plc are listed in the Health Care sector within UK Main Market. Deutsche Bank have set a target price of 5700 GBX on its stock. This now indicates the analyst believes there is a possible upside of 38.1% from the opening price of 4128.5 GBX. Over the last 30 and 90 trading days the company share price has decreased 82 points and decreased 171.5 points respectively. AstraZeneca plc has a 50 day moving average of 4,407.83 GBX and a 200 day moving average of 4,329.91 GBX. The 52 week high share price is 4931.68 GBX while the 52 week low is 3746 GBX. There are currently 1,261,546,027 shares in issue with the average daily volume traded being 3,095,152. Market capitalisation for is 51,994,619,5ase (CKD), diabetes mellitus (DM) and chronic heart failure (CHF). All rights reserved (c) 2016 The Jerusalem Post Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers Envoyer par mail 03 GBP.
27/10/2015
09:44
montyhedge: Update 5th November, get ready for fireworks in the share price, take off like a rocket.
02/5/2014
08:43
harvester: Share price below indicative offer since not all cash offer and risk of pfizer share price weakening as well as risk of the deal failing . AZN share price closed last night at 4851 up 151 based on suspicious after hours trades . At normal market close the share price was 4676.5 . Big money at stake. Hence bound to be some insider trading going on .
28/4/2014
12:14
miata: Citi What's New? - We believe there is a 90% probability that Pfizer acquires AstraZeneca with a take-out price of at least c.£49/share. We reiterate our strong conviction on the compelling strategic and financial rationale. Our stand alone NPV for AZN is £49. Our conservative assumptions on cost cutting, tax and funding costs support an acceptable value-enhancing deal for PFE up to mid-£50s/share price. We have calculated that at £49, an acquisition would have a ROIC of greater than 9% in 2018/19 compared with likely transaction WACC of 5%. We anticipate Core EPS accretion in 2018-20e and beyond up to 12-20%. Full details of the compelling rationale and putative deal structure for PFE/ AZN are in our reports from last week (Pfizer + AstraZeneca. How Did We Miss It? and Pipeline Value Still Underappreciated With or Without PFE. BUY). We first outlined our £49/ share NPV stand-alone value on our November 2013 deep pipeline analysis report (Looking For A Deal, Waiting For The Pipeline). M&A Discussions Confirmed. Pfizer issued a press release this morning under rule 2.4 of the UK Takeover Code. Pfizer announced today that it had held prior discussions with AstraZeneca regarding a potential merger in January 2014, which was discontinued on 14 January. Pfizer confirmed that it had approached AZN again on 26 April seeking to renew discussions, but AZN declined to engage again. PFE had previously made a proposal to the AZN board indicating an acquisition price of £46.61 ($76.62) per share in a combination of cash and stock. We assume last week's offer was £49/share. Pfizer Is Not To Be Deterred. Under the takeover code, Pfizer has a month to decide whether to bid or to withdraw. AZN has commented that they are reviewing Pfizer's more recent offer. Given PFE's articulation of the potential benefits of the deal in today's press release (immediate EPS accretion, value enhancement through portfolio and financial synergies etc.) and the two approaches, we believe that Pfizer will increase pressure on AZN shareholders and board to accept the offer. Notably Pfizer states in their press release "PFE is confident a combination is capable of being consummated". Limited Defence. We continue to believe AZN's bankers will struggle to deliver a strong defence to PFE's approaches. We have previously cited a potential merger-of equals with Abbvie and Amgen. However, these options would deliver less shareholder value than PFE. While theoretically Sanofi could show interest, we think Sanofi would struggle to extract the same level of financial synergies as PFE given PFE's Established Products division and use of offshore cash. We doubt that the UK Government will intercede in any transaction. PFE has committed to retaining a UK and US-based headquarters and will create a financially advantageous UK holding company for both legacy companies increasingly leveraging UK's patent box.
28/4/2014
07:53
buywell2: Another Gap up today to circa 4600p anyone ? Pfizer Inc Statement re Possible Offer 28 April 2014 STATEMENT FROM PFIZER INC. ("PFIZER") ----------------------------------- POSSIBLE OFFER FOR ASTRAZENECA PLC ("ASTRAZENECA") This is an announcement of a possible offer falling under Rule 2.4 of the City Code on Takeovers and Mergers (the "Code"). It does not represent a firm intention to make an offer under Rule 2.7 of the Code. Accordingly, there can be no certainty that any offer will ultimately be made even if the pre-conditions referred to below are satisfied or waived. PFIZER CONFIRMS PRIOR DISCUSSIONS WITH ASTRAZENECA REGARDING A POSSIBLE COMBINATION AND ITS CONTINUING INTEREST IN A POSSIBLE MERGER TRANSACTION -- A transaction would bring together highly complementary Innovative and Established Pharmaceutical Businesses, enhancing the combined company's ability to meet patients' needs -- Both AstraZeneca and Pfizer shareholders would be expected to participate in short, medium and long-term value creation through enhanced pipeline development opportunities, premier global operations and the anticipated realisation of operational and financial synergies Pfizer Inc. confirms that it previously submitted a preliminary, non-binding indication of interest to the board of directors of AstraZeneca in January 2014 regarding a possible merger transaction. After limited high-level discussions, AstraZeneca declined to pursue negotiations. The discussions were discontinued on 14 January 2014 and Pfizer then ceased to consider a possible transaction. In light of recent market developments, Pfizer contacted AstraZeneca on 26 April 2014 seeking to renew discussions in order to develop a proposal that could be recommended by both companies to their shareholders. AstraZeneca again declined to engage. Pfizer is currently considering its options with respect to AstraZeneca. Pfizer's previous proposal made to the board of AstraZeneca on 5 January 2014 included a combination of cash and shares in the combined entity which represented an indicative value of GBP46.61 ($76.62)(1) per AstraZeneca share and a substantial premium of approximately 30% to AstraZeneca's closing share price of GBP35.86 on 3 January 2014. As in its previous proposal, Pfizer is considering a possible transaction in which AstraZeneca shareholders would receive a significant premium for their AstraZeneca shares, to be paid in a combination of cash and shares in the combined entity. Pfizer believes that a transaction, if proposed and consummated, would offer AstraZeneca shareholders a highly compelling opportunity to realise a significant premium to the undisturbed AstraZeneca share price as of 17 April 2014, which includes a substantial cash payment. AstraZeneca shareholders would become significant shareholders in the combined company and participate in significant value creation opportunities, including benefiting from the potential growth opportunities and operational and financial synergies that the combination of two complementary global pharmaceutical companies would be expected to generate. Pfizer is confident a combination is capable of being consummated. The transaction, if consummated, is expected to result in the combination of the two companies under a new U.K.-incorporated holding company. As a global corporation, Pfizer would expect the combined company to have management in both the United States and the United Kingdom, and to maintain head offices in New York and list its shares on the New York Stock Exchange. The making of any firm offer by Pfizer would be subject to the following pre-conditions (which may be waived in whole or in part by Pfizer): (1) Based on Pfizer's closing share price of $30.52 on 3 January 2014 and the exchange rate of $1.00:GBP0.6083. "We have great respect for AstraZeneca and its proud heritage as an innovation-driven biopharmaceutical business with a rich science-based foundation in both the United Kingdom and Sweden. In addition, the United Kingdom has created attractive incentives for companies to manufacture products and maintain and protect intellectual property, and we have seen that capital and jobs have followed these types of incentives. "We believe patients all over the globe would benefit from our shared commitment to R&D, which is critical to the future success of the pharmaceutical industry, in the form of potential new therapies that help to fight some of the world's most feared diseases, such as cancer. "The combination of Pfizer and AstraZeneca could further enhance the ability to create value for shareholders of both companies and bring an expanded portfolio of important treatments to patients. A potential combination with AstraZeneca aligns with Pfizer's current structure and fully supports its existing strategy to build world-class businesses. The combination would complement our two innovative businesses and our Global Established Pharmaceutical business, allowing us to maintain the flexibility for the potential future separation of our businesses whilst at the same time broadening our pipeline breadth and potential new product launches over coming years. We believe that a transaction would further strengthen our ability to generate strong and consistent cash flow, targeted for both investment in our business and return to shareholders, while at the same time offering an efficient operating structure and the anticipated realization of attractive synergies. "As always, we continue to focus on value creation and will be disciplined in our approach to capital deployment. Pfizer has a proven track record of successful acquisitions and, if a transaction were consummated, would use its extensive integration experience to support a successful combination of the businesses and focus on delivering value to shareholders." Pfizer believes the strategic, business and financial rationale for a transaction is compelling. Pfizer believes the possible combination would create a highly complementary mapping of products, pipeline and operating assets to Pfizer's new operating structure, providing additional critical mass to all business segments and strong cash flow through: -- an industry-leading combined portfolio of molecularly targeted medicines for lung cancer, including novel agents for ALK, EGFR and KRas subtypes; -- strengthened presence in breast cancer, including the ongoing phase 3 trial which combines palbociclib with Faslodex for women with recurrent, metastatic hormone-sensitive disease; -- opportunities for greater depth in immuno-oncology, including the option to combine anti-PD-L1 with palbociclib, Xalkori or Inlyta for breast, lung and renal cancer respectively. Additionally, molecules targeting PD-L1, CTLA4 and 41BB offer attractive opportunities for combination immuno-oncology therapy in several cancer indications, including lung cancer and melanoma; -- a strong complementary portfolio of important cardiovascular medicines, such as Brilinta and Eliquis and promising development stage programs, such as bococizumab (PCSK9); -- a broad, innovative commercial offering of non-insulin anti-diabetic medicines that complements Pfizer's early-stage research initiatives and capabilities in diabetes; -- a Global Established Pharmaceutical business with integrated distribution capabilities, expanded reach to healthcare providers and a broad portfolio of market-leading products generating strong and consistent cash flow; and -- a strengthened global footprint and enhanced opportunities in developing markets. The possible transaction is expected to be accretive to Pfizer's adjusted diluted earnings per share(2) in the first full year following the combination(3) . In addition, Pfizer has a track record of realising operational synergies and delivering meaningful value accretion for shareholders in prior transactions of a similar type and scale. Pfizer believes that synergies would be achieved through the combination of the two companies' operations and that the combination would enable greater capital efficiency and a more efficient tax structure. In particular, the currently contemplated structure under a new U.K.-incorporated holding company would not subject AstraZeneca's non-U.S. profits to U.S. tax, which would be in the best interests of the combined company's shareholders. The completion of a possible transaction is subject to the approval of Pfizer's shareholders and is expected to be a taxable event to Pfizer's shareholders. ____________ (2) "Adjusted Income" and its components and "Adjusted Diluted Earnings Per Share (EPS)" are defined as reported U.S. generally accepted accounting principles (GAAP) net income and its components and reported diluted EPS excluding purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items. Pfizer's management uses adjusted income, among other factors, to set performance goals and to measure the performance of the overall company. Pfizer believes that investors' understanding of its performance is enhanced by disclosing this measure. The adjusted income and its components and adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. (3) This is not a statement regarding Pfizer's expectations for its earnings per share for 2014 or subsequent periods. Pfizer reserves the right to introduce other forms of consideration and/or vary the mix of consideration and waive in whole or in part any of the pre-conditions to making an offer. Pfizer reserves the right to make an offer for AstraZeneca at any time for less than the equivalent of GBP46.61 ($76.62) for each AstraZeneca share: (i) with the agreement or recommendation of the AstraZeneca board; (ii) if a third party announces a firm intention to make an offer for AstraZeneca which, as at the date Pfizer announces a firm intention to make an offer for AstraZeneca, is valued at a lower price than the equivalent of GBP46.61 ($76.62) for each AstraZeneca share; (iii) following the announcement by AstraZeneca of a whitewash transaction(4) pursuant to the Code; or (iv) in the event that any AstraZeneca dividend is declared, made or paid in excess of what is expected by the consensus analyst forecasted dividends of 53.6 pence(5) per share due to be announced by AstraZeneca on 31 July 2014, a GBP for GBP adjustment reduction equal to the excess amount. The deadline set by Rule 2.6(a) of the Code (the "Deadline") requires Pfizer either: (i) to announce a firm intention to make an offer for AstraZeneca under Rule 2.7 of the Code; or (ii) to announce that it does not intend to make an offer for AstraZeneca, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies, by not later than 5.00 pm on 26 May 2014, save where either: (i) AstraZeneca and the Takeover Panel have consented to an extension of the Deadline; or (ii) the Deadline does not apply, or ceases to apply, by virtue of Rule 2.6(b) (a firm intention to make an offer for AstraZeneca under Rule 2.7 of the Code being announced by an offeror (other than Pfizer) prior to the Deadline). A copy of this announcement will be available on Pfizer's website at www.pfizer.com. Pfizer will hold an analyst and investor call in respect of this announcement today at 8:30 a.m. EDT (1:30 p.m. BST). A live and recorded webcast will be available from www.pfizer.com. Telephone dial in details (listen only) are as follows: ____________ (4) Broadly, a whitewash transaction is one in which a person, alone or together with parties concerted with such person, acquires or consolidates control in AstraZeneca pursuant to the acquisition of shares issued by AstraZeneca. (5) On the basis of the median consensus analyst forecast full year dividend of $2.80 per share, the split of first interim dividend and second interim dividend over the previous two years, and an exchange rate of $1.00:GBP0.5951.
22/4/2014
12:06
miata: Morgan Stanley Despite PFE's downsizing efforts and AZN's high patent exposure, we think a potential deal could benefit PFE and support AZN shares. It would give PFE access to AZN's diabetes, respiratory and immuno oncology assets while reinforcing PFE's dominant position in China. In line with historical transactions we estimate PFE could shrink c.15% of AZN cost base (ie c.1200p/AZN share, see Exhibit 1). Sunday Times (20 April '14): "Pfizer weighs £60bn bid for AZN" although "AZN is believed to be resisting PFE advances and no talks are currently underway, (...) However, PFE (...) could come back with a fresh approach." Both companies have declined to comment. AZN's main assets are respiratory & diabetes units, immuno oncology and China footprint: A potential deal could benefit PFE given AZN's solid position in respiratory (19% of FY14e revs) and diabetes (7%), and its promising, though early stage, immuno oncology pipeline. It would further reinforce PFE's leading position in China given AZN's strong presence (second after PFE with FY13 sales US$1.84bn, 7% of group). Financial implications: Based on AZN consensus numbers, a £60bn deal ($100bn, 24% premium vs last Friday's close) values AZN at 13.5x EV/EBIT or 12.4x including synergies (15% of its cost base). Our US analyst David Risinger estimates PFE's net cash position at $12bn and assumes PFE could pay with a combination of ex-US cash, new US debt, and equity. A 100% cash deal would imply 3.2x ND/EBITDA, 20%+ EPS accretion and ROCE greater than WACC by 2019e. Likely caveats: PFE would move away from recent downsizing initiatives; AZN's generic exposure: PFE has been refocusing for faster growth off a smaller base (e.g. recent sale of its Nutritional and Animal Health (Zoetis) units). Furthermore, it stated considering exiting old off-patent drugs, while AZN stands to lose 30% of its revenues to generics in the next 3 years (Nexium US 14, Crestor 16/17 and Seroquel XR 17).

Astrazeneca (AZN) Latest Trade

Astrazeneca Most Recent Trade

Trade Type Trade Size Trade Price Trade Date Trade Time Currency
142,693 3,941.00 29 Apr 2016 17:01:23 GBX
Astrazeneca share price data is direct from the London Stock Exchange


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20160430 01:26:49